p53 mutations, described in over 50% of all human cancers, lead not only to p53 loss-of-function, but also to negative-dominant effects (neutralization of the non-mutated p53) and gain-of-function effects, assuring a more aggressive phenotype, i.e., increasing metastatic capacity, genomic instability, and resistance to chemotherapy [53,54]. Here, TP53 is linked to cancer.